FDA Advisory Committee Unanimously Supports Approval of CAR-T Therapies for Multiple Myeloma
Silver Spring, Maryland – The FDA’s Oncologic Drugs Advisory Committee has recently voted on the approvals of CAR-T therapies Carvykti and Abecma as earlier lines of treatment for multiple myeloma. There were concerns raised about the risks of early death in the trials, but ultimately, the committee decided in favor of the approvals. During the meeting, members of the committee discussed the data from the trials, noting higher rates of early deaths in some cases. …